Why PHVS rose 26.7% on Sep 8 2026: positive pivotal trial data
PHVS+26.7%on Tue Sep 8 2026
Pharvaris N.V. Ordinary Shares was up 26.7% on the day at $44.66, ranked #2 on 90.5× its usual five-minute volume, when TapeRank recorded this spike at 07:16 ET during the pre-market session.
WHAT THE ROW LOOKED LIKE
LAST44.66
DAY▲ 26.7%
5 MIN▼ 2.04%
5M RVOL90.5×
5M $VOL$1.4M
FLOAT*65.4M
RANK#2
SESSIONPRE-MARKET
* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
AI VERDICT
JUSTIFIEDCONFIDENCE5/5
Pharvaris shares are up roughly 25% pre-market after announcing positive topline data from the CHAPTER-3 pivotal study of deucrictibant XR for HAE attack prophylaxis, a binding, quantifiable clinical readout rather than a vague partnership. The pullback in the last five minutes reflects normal profit-taking and volatility after the initial pop on heavy volume.
WHYA positive pivotal phase 3 readout is a major binary catalyst for a clinical-stage biotech, and a 25% move is proportionate to de-risking a lead pipeline asset ahead of potential regulatory filing.
ANALYZED 07:17 ET · <1 MIN AGO · ANTHROPIC/CLAUDE-SONNET-5
FILINGS · 24H BEFORE THE MOVE
- 02:51 ET6-K — Foreign issuer reportSEC 6-K
SESSION LEVELS AT CAPTURE
VWAP43.44
HOD48.00
LOD36.95
OR HIGH—
OR LOW—
PREV CLOSE35.25
PM HIGH48.00
PM LOW36.95
GAP▲ 29.79% (indicated)
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO